Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Viking Therapeutics seems to be doubling down on its hopes of making waves in the weight management market as a stand-alone ...

When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off ...

Discover three undervalued biotech stocks with strong assets, solid cash reserves, and major catalysts ahead. Click for the picks and why I like them.

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Viking is in the midst of a Phase 2a dosing trial of VK2735, with a data readout expected in the second half of the year. The company is expected to launch a Phase 3 trial of VK2735 in injectable ...

Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...